Commercial Delta-8 THC Products: an Analysis of Content and Labeling

Kaczor, Eric E.; Greene, Kevin; Babu, Kavita M.; Berthold, Erin C.; Sharma, Abhisheak; Carreiro, Stephanie P.

doi:10.1007/s13181-023-00974-y

Cited by 4 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inaccurate content labeling and potentially harmful adulterants are serious problems in the unregulated cannabinoid market. Products sold under the Δ 8 -THC designation vary considerably with regard to dosing and constituent ingredients . In an analysis of 20 commercial products marketed as Δ 8 -THC, authors observed that 5% of the products did not contain Δ 8 -THC and, among samples that did contain Δ 8 -THC, the quantities in each product varied markedly from advertised values .…”

Section: Policy and Regulatory Backgroundmentioning

confidence: 99%

“…Products sold under the Δ 8 -THC designation vary considerably with regard to dosing and constituent ingredients . In an analysis of 20 commercial products marketed as Δ 8 -THC, authors observed that 5% of the products did not contain Δ 8 -THC and, among samples that did contain Δ 8 -THC, the quantities in each product varied markedly from advertised values . There is also evidence that products sold as Δ 8 -THC contain unlabeled constituents that may be dangerous for consumers .…”

Section: Policy and Regulatory Backgroundmentioning

confidence: 99%

“…The American Association of Poison Control Centers introduced a product code for Δ 8 -THC in 2021, and there was a subsequent increase in calls to poison control centers about Δ 8 -THC . However, products sold as Δ 8 -THC are often contaminated or improperly labeled, calling into question the accuracy of classifying events as related to Δ 8 -THC. More research is needed to characterize the safety of Δ 8 -THC.…”

Section: Monitoring Use and Adverse Eventsmentioning

confidence: 99%

See 2 more Smart Citations

The Public Health Challenge of Δ⁸-THC and Derived Psychoactive Cannabis Products

Whitehill,

Dunn,

Johnson

2024

JAMA

View full text Add to dashboard Cite

In this issue of JAMA, a study by Harlow and colleagues found that 11% of US high school seniors (ie, 12th grade) reported using Δ 8 -tetrahdyrocannabinol (Δ 8 -THC) in the past 12 months based on a 2023 survey. 1 This study is a reminder that there is a diverse set of cannabis products on the market that vary in their legal and regulatory status and potential for harm. 2-5 Δ 8 -THC is a psychoactive cannabinoid that can be derived from hemp. 2,3 It was introduced to the retail market in 2018 and there are indications that its use is on the rise. 4 There is little regulatory oversight of production and sales of Δ 8 -THC and some evidence of adverse outcomes after use. 2,3,5 The unregulated proliferation of Δ 8 -THC represents a potential threat to the public's health. 2,3 In this editorial, we review the legislation that led to the widespread availability of Δ 8 -THC and describe its behavioral pharmacology and potential health harms. This information will assist health professionals in advocating for stronger regulatory oversight of cannabis products and may be useful to health care professionals with patients who use or are considering using Δ 8 -THC.

show abstract

Section: Policy and Regulatory Backgroundmentioning

confidence: 99%

Section: Policy and Regulatory Backgroundmentioning

confidence: 99%

Section: Monitoring Use and Adverse Eventsmentioning

confidence: 99%

See 1 more Smart Citation

The Public Health Challenge of Δ⁸-THC and Derived Psychoactive Cannabis Products

Whitehill,

Dunn,

Johnson

2024

JAMA

View full text Add to dashboard Cite

show abstract

“…Δ9-tetrahydrocannabinol (THC) was the most readily available THC; now due to the perceived legal loophole in the Agriculture Improvement Act of 2018 (formerly known as Farm Bill), Δ8-THC is more widely available, being added in high concentrations to edible products particularly in attractive labels ( United States H.R, 2018 ). A recent study indicated that the amount of Δ8-THC available in the products sold in retail stores had amounts that can cause intoxication ( Kaczor et al, 2024 ).…”

Section: Introductionmentioning

confidence: 99%

Asystole in a young child with tetrahydrocannabinol overdose: a case report and review of literature

Masilamani,

Leff,

Kawai

2024

Front. Toxicol.

View full text Add to dashboard Cite

IntroductionThe association between Δ8-tetrahydrocannabinol (THC) and cardiac dysrhythmia has not been well described in children. Asystole, while consistent with reports of severe bradycardia and apnea in children, is uncommonly described in the current literature. We present the first pediatric case of asystole and apnea following THC ingestion.CaseA 7-year-old male presented to the emergency department (ED) after his mother noticed he was lethargic 3–4 h after accidental ingestion of five 15 mg (total of 75 mg) Δ8-THC gummies. Upon arrival, he was vitally stable and well-appearing. He received maintenance intravenous fluids. Approximately 7 h after initial ingestion, he experienced a >15-s episode of asystole and apnea on telemetry requiring sternal rub to awaken. This was followed by bradycardia (60 beats per minute range) which resolved with 0.1 mg glycopyrrolate. He was admitted to the PICU, drowsy but arousable with stable vitals. After an uneventful 24-h (post-ingestion) PICU observation, he was discharged home in stable condition.DiscussionTo our knowledge, this is the first reported pediatric case of THC-induced asystole. The etiology of asystole may be attributed to direct vagal stimulation of THC or respiratory depression. The typical recommended observation time after potential toxicity is 3–6 h after children have returned to their physiological and behavioral baseline. Our patient was clinically stable with no concern for respiratory depression or cardiac dysrhythmia yet experienced an asystolic pause with apnea 7 h after initial ingestion.ConclusionOur case demonstrates that asystole and apnea may occur in pediatric patients following large THC ingestions and those symptoms can appear late outside of the currently recommended observation period.

show abstract

Severe tianeptine withdrawal symptoms managed with medications for opioid use disorder: a case report

Rawal,

Gallardo,

Henderson

et al. 2023

Journal of Addictive Diseases

View full text Add to dashboard Cite

Commercial Delta-8 THC Products: an Analysis of Content and Labeling

Cited by 4 publications

References 23 publications

The Public Health Challenge of Δ⁸-THC and Derived Psychoactive Cannabis Products

The Public Health Challenge of Δ⁸-THC and Derived Psychoactive Cannabis Products

Asystole in a young child with tetrahydrocannabinol overdose: a case report and review of literature

Severe tianeptine withdrawal symptoms managed with medications for opioid use disorder: a case report

Contact Info

Product

Resources

About

Commercial Delta-8 THC Products: an Analysis of Content and Labeling

Cited by 4 publications

References 23 publications

The Public Health Challenge of Δ8-THC and Derived Psychoactive Cannabis Products

The Public Health Challenge of Δ8-THC and Derived Psychoactive Cannabis Products

Asystole in a young child with tetrahydrocannabinol overdose: a case report and review of literature

Severe tianeptine withdrawal symptoms managed with medications for opioid use disorder: a case report

Contact Info

Product

Resources

About

The Public Health Challenge of Δ⁸-THC and Derived Psychoactive Cannabis Products

The Public Health Challenge of Δ⁸-THC and Derived Psychoactive Cannabis Products